{"nctId":"NCT01377194","briefTitle":"Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder","startDateStruct":{"date":"2011-06"},"conditions":["Major Depressive Disorder"],"count":568,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran ER"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran ER"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Levomilnacipran ER","otherNames":[]},{"name":"Levomilnacipran ER","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women, 18-75 years old\n* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder\n* The patient's current depressive episode must be at least 6 weeks in duration\n\nExclusion Criteria:\n\n* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control.\n* Patients who are considered a suicide risk\n* Patients with a history of meeting DSM-IV-TR criteria for\n* a. any manic or hypomanic episode\n* b. schizophrenia or any other psychotic disorder\n* c. obsessive-compulsive disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.","description":"The Montgomery-Asberg Depression Rating Scale (MADRS) rates patients on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest. Each item was scored on a 7-point scale. A score of 0 indicated the absence of symptoms, and a score of 6 indicated symptoms of maximum severity. The minimum overall score possible was 0 (absence of symptoms), with a maximum overall score of 60 (maximum severity).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.3","spread":"0.77"},{"groupId":"OG001","value":"-14.6","spread":"0.79"},{"groupId":"OG002","value":"-14.4","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"Change in Sheehan Disability Scale (SDS) Total Score","description":"The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"0.66"},{"groupId":"OG001","value":"-7.3","spread":"0.68"},{"groupId":"OG002","value":"-8.2","spread":"0.66"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":186},"commonTop":["Nausea","Headache","Dry mouth","Constipation","Upper respiratory tract infection"]}}}